Special considerations regarding antiretroviral therapy and infection prophylaxis in the HIV-infected individual with cancer.
Sparano
J A
JA
Montefiore Medical Center, Albert Einstein Comprehensive Cancer Center, Albert Einstein College of Medicine, USA.
Kalkut
G
G
D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active; D018791:CD4 Lymphocyte Count; D003657:Decision Making; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D009369:Neoplasms / Q000150:complications; D009894:Opportunistic Infections / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011480:Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D013727:Terminal Care; D019562:Viral Load
D019380:Anti-HIV Agents; D000970:Antineoplastic Agents; D011480:Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors